14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:DRNA
Delisted

Dicerna Pharmaceuticals Stock Price (Quote)

$38.22
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $38.22 $38.22 Friday, 27th May 2022 DRNA stock ended at $38.22. During the day the stock fluctuated 0% from a day low at $38.22 to a day high of $38.22.
90 days $38.22 $38.22
52 weeks $19.06 $40.14

Historical Dicerna Pharmaceuticals prices

Date Open High Low Close Volume
Mar 27, 2019 $13.67 $13.83 $13.24 $13.60 340 190
Mar 26, 2019 $13.39 $13.69 $13.21 $13.67 247 605
Mar 25, 2019 $13.19 $13.40 $12.68 $13.29 312 630
Mar 22, 2019 $13.96 $14.16 $13.26 $13.29 427 116
Mar 21, 2019 $13.47 $14.18 $13.36 $14.04 309 113
Mar 20, 2019 $13.43 $13.88 $13.23 $13.61 306 582
Mar 19, 2019 $13.17 $13.52 $12.95 $13.33 372 084
Mar 18, 2019 $12.91 $13.53 $12.91 $13.10 550 526
Mar 15, 2019 $12.40 $13.28 $12.34 $12.91 1 328 495
Mar 14, 2019 $11.65 $12.41 $11.56 $12.31 686 063
Mar 13, 2019 $11.74 $11.75 $11.25 $11.60 482 288
Mar 12, 2019 $11.23 $11.95 $11.00 $11.48 2 180 256
Mar 11, 2019 $10.78 $11.85 $10.78 $11.74 931 976
Mar 08, 2019 $11.07 $11.34 $10.70 $10.93 1 072 458
Mar 07, 2019 $11.95 $11.95 $11.08 $11.10 1 807 715
Mar 06, 2019 $12.79 $12.82 $11.84 $11.99 864 867
Mar 05, 2019 $12.78 $13.01 $12.60 $12.77 780 544
Mar 04, 2019 $12.96 $13.09 $12.44 $12.78 1 049 943
Mar 01, 2019 $12.33 $12.96 $12.19 $12.93 690 103
Feb 28, 2019 $12.00 $12.48 $11.69 $12.21 1 144 082
Feb 27, 2019 $11.22 $12.13 $11.19 $12.08 502 963
Feb 26, 2019 $10.80 $11.52 $10.61 $11.28 909 130
Feb 25, 2019 $10.72 $10.80 $10.38 $10.69 620 938
Feb 22, 2019 $10.77 $10.79 $10.23 $10.51 411 847
Feb 21, 2019 $10.44 $10.76 $10.15 $10.74 315 071
Click to get the best stock tips daily for free!

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherit... DRNA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT